Frost & Sullivan conducted an economic analysis to estimate the potential cost savings of supplementing all pregnant women with protective levels of algal DHA, to reduce the impact of preterm and early preterm births. Considering both the efficacy and cost of DHA, Frost & Sullivan estimates that universal supplementation would have reduced net direct hospital costs associated with preterm birth by nearly 4.6 billion dollars in 2021, with the total net savings (including lifetime costs associated with preterm birth-associated comorbidities) being $7.39 billion. Between 2023 and 2030, the expected cumulative potential direct and indirect net savings is expected to be nearly $67 billion.
